Estrogen and progestogen effect on venous thromboembolism in menopausal women

Climacteric

Volumn 15, Issue 3, 2012, Pages 235-240

  Archer, D F ^a   Oger, E ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b INSERM   (France)

Author keywords

ESTROGEN; POSTMENOPAUSAL WOMEN; PROGESTOGEN; TRANSDERMAL; VENOUS THROMBOEMBOLISM

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PREGNANE DERIVATIVE;

AGING; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG EFFECT; EUROPE; FEMALE; GENETIC MARKER; HORMONAL THERAPY; HUMAN; LUNG EMBOLISM; OBESITY; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; AGE FACTORS; AGED; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PROGESTINS; RISK FACTORS; VENOUS THROMBOSIS; WOMEN'S HEALTH;

EID: 84861399620     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.664401     Document Type: Review

References (43)

1. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-80
2. Cushman M, Kuller LH, Prentice R, et al . Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292: 1573-80 (Pubitemid 39314963)
3. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:14-8
4. Barlow DH. HRT and the risk of deep vein thrombosis. Int JGynaecol Obstet 1997;59(Suppl 1):S29-33
5. Grady D, Wenger NK, Herrington D, et al . Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689-96 (Pubitemid 30244167)
6. Dinger J, Assmann A, Mohner S, Minh TD. Risk of venous thromboembolism and the use of dienogest-and drospirenonecontaining oral contraceptives: results from a German casecontrol study. J Fam Plann Reprod Health Care 2010;36: 123-9
7. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of adrospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54 (Pubitemid 46551071)
8. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151
9. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342:d2139
10. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921
11. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5 (Pubitemid 46294724)
12. Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. Drugs Aging 1999;14:323-36 (Pubitemid 29213773)
13. Cummings SR, Eckert S, Krueger KA, et al . The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97 (Pubitemid 29275701)
14. Anderson GL, Limacher M, Assaf AR, et al . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12 (Pubitemid 38489892)
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
16. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14
17. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45 (Pubitemid 351347060)
18. Canonico M, Plu-Bureau G, Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas 2011;70:354-60
19. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-5
20. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80 (Pubitemid 26340751)
21. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997;314:796-800
22. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998;147:387-90
23. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism-apopulation-based case-control study. Thromb Haemost 1999;82: 1218-21 (Pubitemid 29473780)
24. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32 (Pubitemid 36999704)
25. Douketis JD, Julian JA, Kearon C, et al . Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2005;3:943-8 (Pubitemid 41632824)
26. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-31 (Pubitemid 351809317)
27. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a populationbased study. J Thromb Haemost 2010;8:979-86
28. Conard J, Samama M, Basdevant A, Guy-Grand B, de Lignieres B. Differential AT III-response to oral and parenteral administration of 17 beta-estradiol. Thromb Haemost 1983;49:252 (Pubitemid 13060104)
29. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001;115:415-20 (Pubitemid 34203511)
30. Hoibraaten E, Os I, Seljefl ot I, Andersen TO, Hofstad A, Sandset PM. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verifi ed coronary artery disease: results from the Estrogen in Women with Atherosclerosis Study. Thrombosis Res 2000;98:19-27 (Pubitemid 30114257)
31. Marque V, Alhenc-Gelas M, Plu-Bureau G, Oger E, Scarabin PY. The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women. Thromb Haemost 2001;86:713-14 (Pubitemid 32743291)
32. Oger E, Alhenc-Gelas M, Lacut K, et al . Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-6 (Pubitemid 37108215)
33. Post MS, Christella M, Thomassen LG, et al . Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebocontrolled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-21 (Pubitemid 36713570)
34. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fi brinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8 (Pubitemid 28016061)
35. Teede HJ, McGrath BP, Smolich JJ, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fi brinolysis. Arterioscler Thromb Vasc Biol 2000;20:1404-9 (Pubitemid 30262946)
36. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al . Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fi brinolysis, infl ammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25 (Pubitemid 32293696)
37. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999;130:643-50 (Pubitemid 29196198)
38. Dahlback B. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997;78:483-8 (Pubitemid 27289289)
39. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-6 (Pubitemid 29076142)
40. Eilertsen AL, Liestol S, Mowinckel MC, Hemker HC, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost 2007;97:938-43 (Pubitemid 46939206)
41. Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008; 90:642-72
42. Harman SM, Brinton EA, Cedars M, et al . KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12 (Pubitemid 40675116)
43. http://clinicaltrials.gov/ct2/show/NCT00114517 accessed 19 January 2012